In this episode I spoke with Nathaniel Lipkus, intellectual property litigator, and partner at Osler, Hoskin & Harcourt LLP.
Nate is a legal expert on patent and regulatory issues facing pharmaceutical and biotechnology companies.
Nate has also published extensively on topics pertaining to Canada’s Patent Act . Nate recently wrote an article for the Globe and Mail exploring today’s topic.
In this episode, Nate provides insight on Canada's regulatory framework and how it can assist Canadian access to new therapeutics to the novel coronavirus. Specifically, we explore the COVID-19 Emergency Response Act (Bill C-13) and its provisions.
We also explore Canada’s industrial capability to meet future demand to treatment.